Aptahem’s presentation at the BioStock Investor Meeting now available

2023-09-27

Aptahem’s CEO Mikael Lindstam presented the company and gave an update on the ongoing activities at the BioStock Investor Meeting on 20 September 2023. The presentation, which is held in English, and an interview, in Swedish, are now available...

Read More

Aptahem reports promising outcome from the additional analyses on the mechanism on lead candidate Apta-1 in the FIH study

2023-09-15

Aptahem AB (publ) announces today that the results from the additional analyses performed in cohorts 1 to 4 in the First in Human (FIH) study, have contributed to the clarification of Apta-1’s impact on clinical biomarkers. Next step is...

Read More

Analyst Groups Aptahem-analys: I väntan på återupptagen studie

2023-09-06

Analyst Group publicerade idag en analys av Aptahem med titeln ”I väntan på återupptagen studie” som kan läsas på Analyst Groups webbsida och på www.aptahem.com. För ytterligare information: Aptahem AB Mikael Lindstam, VD Tel: 0766-33 36 99 Epost: ml@aptahem.com...

Read More

Aptahem attends the BioStock Investor Meeting on 20 September 2023

2023-09-05

Aptahem’s CEO Mikael Lindstam is presenting the company and gives an update on the ongoing activities. The presentation, which is held in English, can be followed at the physical event in Stockholm on 20 September at 15.00 CET. More...

Read More

BioStock article: Aptahem’s CEO comments on Q2 and looks ahead

2023-09-05

BioStock published an article on 5 September 2023 about Aptahem, which can be read in full below. For Aptahem, the second quarter continued to focus on the clinical development of drug candidate Apta-1 against sepsis. However, the company recently...

Read More

Aptahems delårsrapport 2023-04-01 till 2023-06-30

2023-08-31

Sammanfattning av delårsrapport Andra kvartalet (2023-04-01 – 2023-06-30) Rörelsens intäkter uppgick till 411 (1 127) KSEK Resultat efter finansiella poster -2 736 (-1 793) KSEK Resultat per aktie -0,02 (-0,01) SEK Likvida medel uppgick per 2023-06-30 till 5 782...

Read More

Aptahem comments on the paused phase I study

2023-07-24

BioStock published an article on 24 July 2023 about Aptahem, which can be read in full below. Aptahem develops the drug candidate Apta-1 as an acute treatment of sepsis. Recently, the company announced that the ongoing phase Ia study...

Read More

In Aptahem’s FIH study further analytic studies will be performed

2023-07-17

Aptahem AB (publ), a biotech company developing treatments for patients suffering from acute inflammatory diseases such as sepsis, announces today that in the double-blinded randomized placebo controlled first-in-human (FIH) clinical trial further analytic studies on the mechanism of Apta-1...

Read More

Aptahems företrädesemission är registrerad och handel med BTA upphör

2023-07-06

EJ FÖR OFFENTLIGGÖRANDE, DISTRIBUTION ELLER PUBLICERING, VARE SIG DIREKT ELLER INDIREKT, INOM ELLER TILL USA, AUSTRALIEN, BELARUS, HONGKONG, JAPAN, KANADA, NYA ZEELAND, RYSSLAND, SCHWEIZ, SINGAPORE, SYDAFRIKA, SYDKOREA ELLER I NÅGON ANNAN JURISDIKTION DÄR OFFENTLIGGÖRANDE, DISTRIBUTION ELLER PUBLICERING AV DETTA...

Read More

Aptahem AB (publ) offentliggör utfall i företrädesemission

2023-06-29

EJ FÖR OFFENTLIGGÖRANDE, DISTRIBUTION ELLER PUBLICERING, VARE SIG DIREKT ELLER INDIREKT, INOM ELLER TILL USA, AUSTRALIEN, BELARUS, HONGKONG, JAPAN, KANADA, NYA ZEELAND, RYSSLAND, SCHWEIZ, SINGAPORE, SYDAFRIKA, SYDKOREA ELLER I NÅGON ANNAN JURISDIKTION DÄR OFFENTLIGGÖRANDE, DISTRIBUTION ELLER PUBLICERING AV DETTA...

Read More